--- title: "AnaptysBio to participate in investor conferences. CEO to attend for discussions on immunology therapeutics." type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/275036939.md" description: "Today, February 5, 2026, San Diego-based biotechnology company AnaptysBio, Inc. (Nasdaq: ANAB) revealed plans for its involvement in various investor conferences. Daniel Faga, the president and CEO of Anaptys, along with other key executives, will be engaging in these conferences. AnaptysBio specializes in developing groundbreaking immunology treatments and is currently in the clinical stage of its operations." datetime: "2026-02-05T21:38:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275036939.md) - [en](https://longbridge.com/en/news/275036939.md) - [zh-HK](https://longbridge.com/zh-HK/news/275036939.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275036939.md) | [English](https://longbridge.com/en/news/275036939.md) # AnaptysBio to participate in investor conferences. CEO to attend for discussions on immunology therapeutics. Today, February 5, 2026, San Diego-based biotechnology company AnaptysBio, Inc. (Nasdaq: ANAB) revealed plans for its involvement in various investor conferences. Daniel Faga, the president and CEO of Anaptys, along with other key executives, will be engaging in these conferences. AnaptysBio specializes in developing groundbreaking immunology treatments and is currently in the clinical stage of its operations. ### 相關股票 - [Anaptysbio (ANAB.US)](https://longbridge.com/zh-HK/quote/ANAB.US.md) ## 相關資訊與研究 - [What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings?](https://longbridge.com/zh-HK/news/278095134.md) - [AnaptysBio Chief Legal Officer Sells 10,000 Shares](https://longbridge.com/zh-HK/news/275944539.md) - [BUZZ-AnaptysBio climbs on plans to split into two public companies](https://longbridge.com/zh-HK/news/277810200.md) - [AnaptysBio (NASDAQ:ANAB) Shares Gap Down Following Insider Selling](https://longbridge.com/zh-HK/news/272097005.md) - [AnaptysBio to Split Biopharma Operations and Royalty Assets by 2026](https://longbridge.com/zh-HK/news/271698933.md)